TTY Biopharm Co Ltd (4105) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of TTY Biopharm Co Ltd stock TWD 110, price TWD 79.20, upside +38.8%, quality 80 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 2, 2026.
How to read this chart
60‑month range 60.94 TWD – 86.30 TWD · fair‑value band 78.76 TWD – 136.66 TWD · the 79.20 TWD price screens below the 109.90 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 2, 2026.
Follow TTY Biopharm Co in your weekly email
Every Wednesday you see whether TTY Biopharm Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally.
Show moreShow less
The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments.
It offers oncology drugs for the treatment of anticancer and adjunctive therapies under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Yondelis, Pemazyre, Pulmivex, Xpovio, Minjuvi, and Fustron names.
The company also provides anti-infective drugs and anesthetics to treat second-line antimicrobial agents, influenza, and anesthetics under the Brosym, Bobimixyn, Colimycin, Cubicin, Lipo-AB, Flusine, Maxtam, Metacin, Flucelvax, Fluad, and Byfavo names; and healthcare products for the treatment of gastrointestinal health, bone health, and metabolic regulation under the Algitab, Alginos, Bio-Cal Plus, Sulfin names.
In addition, it offers contract development and manufacturing (CDMO) services. The company was incorporated in 1960 and is headquartered in Taipei, Taiwan.
Stock analysis
TTY Biopharm Co Ltd (4105) currently trades at 79.20 TWD, while our model-based Fair Value estimate is 109.90 TWD, implying the stock looks roughly 28% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 126.61 TWD per share, and 18 of the 26 models we run sit above the 79.20 TWD price.
Bear case: the Earnings-Based group reads lowest at 57.17 TWD, and 8 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 78.76 TWD (bear) to 136.66 TWD (bull), the price of 79.20 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 80/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
TTY Biopharm Co Ltd reported revenue of 6.5B TWD in FY2025 versus 4.5B TWD in FY2021, a compound +9.2%/yr. Reported net income was 1.6B TWD in FY2025, compounding +17.0%/yr from FY2021.
Key figures
Market cap 19.7B TWD (≈ $601M) Small · P/E ratio 11.4 · P/S ratio 2.96 · EPS (TTM) 6.96 TWD · Dividend yield 5.7% · Net margin 26.0% · Return on equity 25.1% · Return on assets (EBIT) 13.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 86 out of 100 (low confidence).
What moves the price
The share trades about 8% below its 52-week high and 10% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 39%, 4105 screens cheaper than that median.
Fair Value models
Bear78.76 TWDFair Value 109.90 TWDBull136.66 TWD
Price 79.20 TWD · Upside +38.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (2.10 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.88/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+9.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.9%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.9%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+12.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+7.1%
Dividend (yield on the price)5.7%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.29% → 26%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+0.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about −1.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score80 · Top 25%
Fair Value upside+38.8% · Top 25%
Profitability
Return on equity (12 months)25.1% · Top 25%
Return on assets13.7% · Top 25%
Net margin (12 months)26.0% · Top 25%
Operating margin (12 months)29.5% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)9.2% · Above median
Dividend yield (12 months)5.7% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)11.4× · Cheapest 25%
P/B2.72× · Pricier than median
P/S (12 months)2.96× · Pricier than median
Price / free cash flow (fiscal year)12.2× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "TTY Biopharm Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/4105
Frequently asked questions
Is TTY Biopharm Co Ltd (4105) overvalued or undervalued?
As of Nov 2, 2026, our model estimates a fair value of 109.90 TWD versus a price of 79.20 TWD, about +39% upside (undervalued).
What is the fair value of 4105?
Our model-based fair value for TTY Biopharm Co Ltd is 109.90 TWD (as of Nov 2, 2026), built from audited fundamentals. The current price: 79.20 TWD.
What is the quality score of 4105?
TTY Biopharm Co Ltd has a Quality Score of 80/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for TTY Biopharm Co Ltd (4105)?
Our model-based price target is the fair value of 109.90 TWD (as of Nov 2, 2026) from 26 valuation models. Cautious scenario 78.76 TWD, optimistic scenario 136.66 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the TTY Biopharm Co Ltd stock forecast for 2026?
Our models put fair value at 109.90 TWD, about +39% upside versus a price of 79.20 TWD (undervalued). Cautious scenario 78.76 TWD, optimistic scenario 136.66 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of TTY Biopharm Co Ltd (4105)?
TTY Biopharm Co Ltd reported trailing-twelve-month revenue of about 6.7B TWD (latest available figure, as of Nov 2, 2026).
Does TTY Biopharm Co Ltd pay a dividend?
TTY Biopharm Co Ltd currently shows a dividend yield of 5.68% relative to its recent price (as of Nov 2, 2026).
How much is the dividend of TTY Biopharm Co Ltd (4105) and when is the ex-dividend date?
TTY Biopharm Co Ltd pays a dividend of 4.50 TWD per share a year, a dividend yield of 5.7%. The last ex-dividend date was Mar 26, 2026. A dividend has been paid every year since at least 2008. The payout ratio is 64.7% of earnings. Free cash flow covers the dividend 1.44 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into TTY Biopharm Co Ltd (4105)?
For today's price to be fair in a discounted-cash-flow model, TTY Biopharm Co Ltd would have to grow free cash flow by +0.4 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.9 % per year. As of Nov 2, 2026.
What discount rate (WACC) does the fair value of 4105 use?
Our models discount TTY Biopharm Co Ltd at 10.3 %: a base by market capitalisation (small), damped by beta 0.09, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For TTY Biopharm Co Ltd that is +0.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has TTY Biopharm Co Ltd (4105) delivered so far?
Over the past 5 years revenue at TTY Biopharm Co Ltd grew +8.9 % a year. The price currently implies free-cash-flow growth of +0.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of TTY Biopharm Co Ltd (4105) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into TTY Biopharm Co Ltd (+0.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of TTY Biopharm Co Ltd (4105)?
The free-cash-flow yield on the price is 8.18 %: that much free cash flow TTY Biopharm Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of TTY Biopharm Co Ltd (4105)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For TTY Biopharm Co Ltd it is 109.90 TWD per share (as of Nov 2, 2026), against a price of 79.20 TWD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is TTY Biopharm Co Ltd stock overvalued or undervalued in 2026?
As of Nov 2, 2026, 4105 trades below its calculated fair value: price 79.20 TWD, fair value 109.90 TWD, a gap of about +39% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4105?
No. The price is what the market pays today (79.20 TWD); the fair value is what the company's own numbers justify (109.90 TWD). For TTY Biopharm Co Ltd the two are 30.70 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is TTY Biopharm Co Ltd worth?
The market values TTY Biopharm Co Ltd at about 19.7B TWD (market capitalisation, as of Nov 2, 2026). Per share that is 79.20 TWD; our models calculate a fair value of 109.90 TWD per share.
What do the bullish and bearish scenarios say about 4105?
Our models span a range for TTY Biopharm Co Ltd: cautious scenario 78.76 TWD, base 109.90 TWD, optimistic 136.66 TWD per share (as of Nov 2, 2026, price 79.20 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4105?
TTY Biopharm Co Ltd trades at a price-to-earnings ratio of 11.4 (as of Nov 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 109.90 TWD is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2017 to 2025), reported earnings: 18.5. Other multiples: P/B 2.7, P/S 3.0, EV/EBITDA 8.3.
How solid is the balance sheet of TTY Biopharm Co Ltd (4105)?
Balance-sheet figures for TTY Biopharm Co Ltd (as of Nov 2, 2026): return on equity 25.1%. They feed the Quality Score of 80/100, which measures business quality independently of the share price.
How far is 4105 from its 52-week high?
TTY Biopharm Co Ltd trades at 79.20 TWD, about 8% below its 52-week high of 86.30 TWD and 10% above the low of 72.10 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 109.90 TWD is for.
Which stocks are comparable to TTY Biopharm Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is TTY Biopharm Co Ltd stock attractive at the current price?
The data as of Nov 2, 2026: price 79.20 TWD, calculated fair value 109.90 TWD (+39%), Quality Score 80/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4105 calculated?
We run TTY Biopharm Co Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 109.90 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. TTY Biopharm Co Ltd currently trades 28% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of TTY Biopharm Co Ltd (4105)?
The closing price on Nov 6, 2026 was 79.20 TWD. Our model-based fair value is 109.90 TWD, about +39% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with TTY Biopharm Co Ltd right now?
The rarer combination: high quality (80/100) AND below fair value. That earns a closer look rather than a quick verdict. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of TTY Biopharm Co Ltd
How large is the market capitalisation of TTY Biopharm Co Ltd (4105)?
The market capitalisation of TTY Biopharm Co Ltd is 19.7B TWD (≈ $601M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of TTY Biopharm Co Ltd (4105)?
The price-to-sales ratio of TTY Biopharm Co Ltd is 2.96 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of TTY Biopharm Co Ltd (4105)?
Earnings per share at TTY Biopharm Co Ltd are 6.96 TWD (price ÷ EPS = P/E 11.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of TTY Biopharm Co Ltd (4105)?
The dividend yield of TTY Biopharm Co Ltd is 5.7% (payout 64.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of TTY Biopharm Co Ltd (4105)?
The net margin of TTY Biopharm Co Ltd is 26.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of TTY Biopharm Co Ltd (4105)?
The return on equity (ROE) of TTY Biopharm Co Ltd is 25.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of TTY Biopharm Co Ltd (4105)?
On an EBIT basis the return on assets of TTY Biopharm Co Ltd is 13.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of TTY Biopharm Co Ltd (4105)?
The operating margin of TTY Biopharm Co Ltd is 29.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at TTY Biopharm Co Ltd (4105)?
Revenue at TTY Biopharm Co Ltd is growing +9.2% versus a year earlier (3y avg +8.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at TTY Biopharm Co Ltd (4105)?
Earnings per share at TTY Biopharm Co Ltd are growing +43.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does TTY Biopharm Co Ltd (4105) hold?
TTY Biopharm Co Ltd holds more cash than debt, 706M TWD net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch TTY Biopharm Co Ltd in the live analysis
One click puts TTY Biopharm Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 2, 2026